Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glofitamab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07599423
What this trial is testing

Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University 96
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07326371
What this trial is testing

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Ruijin Hospital 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06047080
What this trial is testing

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma
Hoffmann-La Roche 1,130
Early research (Phase 1)Not Yet RecruitingNCT07649304
What this trial is testing

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

Who this might be right for
AIDS-Related Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements+6 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Looking for participantsNCT06806033
What this trial is testing

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Who this might be right for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche 130
Testing effectiveness (Phase 2)Looking for participantsNCT06867536
What this trial is testing

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Lymphoma
Liling Zhang 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06567366
What this trial is testing

CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

Who this might be right for
Large B-cell Lymphoma
Ruijin Hospital 45
Testing effectiveness (Phase 2)UnknownNCT04914741
What this trial is testing

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
Peter MacCallum Cancer Centre, Australia 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT06552572
What this trial is testing

Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Diffuse Large B Cell Lymphoma
Samsung Medical Center 30